These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 29914602)

  • 21. Impact of adverse drug reactions on the incremental cost-effectiveness of bedaquiline for drug-resistant tuberculosis.
    Schnippel K; Firnhaber C; Page-Shipp L; Sinanovic E
    Int J Tuberc Lung Dis; 2018 Aug; 22(8):918-925. PubMed ID: 29991402
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study.
    Bonnet M; Bastard M; du Cros P; Khamraev A; Kimenye K; Khurkhumal S; Hayrapetyan A; Themba D; Telnov A; Sanchez-Padilla E; Hewison C; Varaine F
    Int J Tuberc Lung Dis; 2016 Feb; 20(2):177-86. PubMed ID: 26792469
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modeling the impact of bedaquiline treatment strategies on the multidrug-resistant tuberculosis burden in India.
    Mehra M; Kambili C; Potluri R; Rhines A; Singh V; Thomas A
    Int J Tuberc Lung Dis; 2017 Aug; 21(8):902-909. PubMed ID: 28786799
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bedaquiline for multidrug-resistant TB in paediatric patients.
    Moodliar R; Aksenova V; Frias MVG; van de Logt J; Rossenu S; Birmingham E; Zhuo S; Mao G; Lounis N; Kambili C; Bakare N
    Int J Tuberc Lung Dis; 2021 Sep; 25(9):716-724. PubMed ID: 34802493
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis.
    Achar J; Hewison C; Cavalheiro AP; Skrahina A; Cajazeiro J; Nargiza P; Herboczek K; Rajabov AS; Hughes J; Ferlazzo G; Seddon JA; du Cros P
    Emerg Infect Dis; 2017 Oct; 23(10):1711-3. PubMed ID: 28758889
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
    Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
    Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa.
    Mpobela Agnarson A; Williams A; Kambili C; Mattson G; Metz L
    Expert Rev Anti Infect Ther; 2020 May; 18(5):475-483. PubMed ID: 32186925
    [No Abstract]   [Full Text] [Related]  

  • 28. Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis: Promising but challenging.
    Li Y; Sun F; Zhang W
    Drug Dev Res; 2019 Feb; 80(1):98-105. PubMed ID: 30548290
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of Bedaquiline Combined with Fluoroquinolone and/or Clofazimine on QT Interval in Patients with Multidrug-Resistant Tuberculosis: a Retrospective Study.
    Li R; Ma JB; Yang H; Yang H; Yang XJ; Wu YQ; Ren F
    Microbiol Spectr; 2023 Aug; 11(4):e0104823. PubMed ID: 37310268
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs.
    Huerga H; Khan U; Bastard M; Mitnick CD; Lachenal N; Khan PY; Seung KJ; Melikyan N; Ahmed S; Rich ML; Varaine F; Osso E; Rashitov M; Salahuddin N; Salia G; Sánchez E; Serobyan A; Rafi Siddiqui M; Grium Tefera D; Vetushko D; Yeghiazaryan L; Holtzman D; Islam S; Kumsa A; Jacques Leblanc G; Leonovich O; Mamsa S; Manzur-Ul-Alam M; Myint Z; Padayachee S; Franke MF; Hewison C
    Clin Infect Dis; 2022 Oct; 75(8):1307-1314. PubMed ID: 35243494
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study.
    Borisov SE; Dheda K; Enwerem M; Romero Leyet R; D'Ambrosio L; Centis R; Sotgiu G; Tiberi S; Alffenaar JW; Maryandyshev A; Belilovski E; Ganatra S; Skrahina A; Akkerman O; Aleksa A; Amale R; Artsukevich J; Bruchfeld J; Caminero JA; Carpena Martinez I; Codecasa L; Dalcolmo M; Denholm J; Douglas P; Duarte R; Esmail A; Fadul M; Filippov A; Davies Forsman L; Gaga M; Garcia-Fuertes JA; García-García JM; Gualano G; Jonsson J; Kunst H; Lau JS; Lazaro Mastrapa B; Teran Troya JL; Manga S; Manika K; González Montaner P; Mullerpattan J; Oelofse S; Ortelli M; Palmero DJ; Palmieri F; Papalia A; Papavasileiou A; Payen MC; Pontali E; Robalo Cordeiro C; Saderi L; Sadutshang TD; Sanukevich T; Solodovnikova V; Spanevello A; Topgyal S; Toscanini F; Tramontana AR; Udwadia ZF; Viggiani P; White V; Zumla A; Migliori GB
    Eur Respir J; 2017 May; 49(5):. PubMed ID: 28529205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the United States.
    Mase S; Chorba T; Parks S; Belanger A; Dworkin F; Seaworth B; Warkentin J; Barry P; Shah N
    Clin Infect Dis; 2020 Aug; 71(4):1010-1016. PubMed ID: 31556947
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic interaction between bedaquiline and clofazimine in patients with drug-resistant tuberculosis.
    Maartens G; Brill MJE; Pandie M; Svensson EM
    Int J Tuberc Lung Dis; 2018 Jan; 22(1):26-29. PubMed ID: 29145924
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term plasma pharmacokinetics of bedaquiline for multidrug- and extensively drug-resistant tuberculosis.
    Perrineau S; Lachâtre M; Lê MP; Rioux C; Loubet P; Fréchet-Jachym M; Gonzales MC; Grall N; Bouvet E; Veziris N; Yazdanpanah Y; Peytavin G
    Int J Tuberc Lung Dis; 2019 Jan; 23(1):99-104. PubMed ID: 30674381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment outcomes in patients with drug-resistant TB-HIV co-infection treated with bedaquiline and linezolid.
    Padayatchi N; Bionghi N; Osman F; Naidu N; Ndjeka N; Master I; Brust JCM; Naidoo K; Ramjee A; O Donnell M
    Int J Tuberc Lung Dis; 2020 Oct; 24(10):1024-1031. PubMed ID: 33126934
    [No Abstract]   [Full Text] [Related]  

  • 36. Primary bedaquiline resistance in Karakalpakstan, Uzbekistan.
    Moe S; Rekart ML; Hernandez D; Sholpan A; Ismailov A; Oluya M; Bayniyazova A; Zinaida T; Nargiza P; Gomez-Restrepo C; Sitali N; Sinha A
    Int J Tuberc Lung Dis; 2023 May; 27(5):381-386. PubMed ID: 37143220
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bedaquiline and Repurposed Drugs for Fluoroquinolone-Resistant Multidrug-Resistant Tuberculosis: How Much Better Are They?
    Bastard M; Guglielmetti L; Huerga H; Hayrapetyan A; Khachatryan N; Yegiazaryan L; Faqirzai J; Hovhannisyan L; Varaine F; Hewison C
    Am J Respir Crit Care Med; 2018 Nov; 198(9):1228-1231. PubMed ID: 29969054
    [No Abstract]   [Full Text] [Related]  

  • 38. Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea.
    Kim CT; Kim TO; Shin HJ; Ko YC; Hun Choe Y; Kim HR; Kwon YS
    Eur Respir J; 2018 Mar; 51(3):. PubMed ID: 29545276
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Profile of Multidrug Tuberculosis Regimen and Treatment Outcomes in Pulmonary MDR-TB Patients at the Tertiary Referral Hospital Dr. Soetomo, East Java, Indonesia: A Seven-Year Retrospective Study on Bedaquiline.
    Setyawan MF; Mertaniasih NM; Soedarsono S
    Acta Med Indones; 2023 Oct; 55(4):430-439. PubMed ID: 38213049
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acquired bedaquiline resistance in Karakalpakstan, Uzbekistan.
    Nair P; Hasan T; Zaw KK; Allamuratova S; Ismailov A; Mendonca P; Bekbaev Z; Parpieva N; Singh J; Sitali N; Bermudez-Aza E; Sinha A
    Int J Tuberc Lung Dis; 2022 Jul; 26(7):658-663. PubMed ID: 35768925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.